pharmadog
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
Hubs
  • Topics
  • Patent cliff
  • Publications
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
pharmadog news

Browse

799 stories matching this filter · ← front page

★ save view↓export CSV
rangeto
sort
recentoldestsourcealpha
source
STAT776Endpoints580BioPharma Dive223onclive165Fierce Biotech54BioSpace52raps24
therapy area
allOncology81Cardiology27Psychiatry & CNS21Vaccines17Immunology17Rare Disease12Hepatology6
  • Lilly gives hospitals deadline to comply with 340B claims data policy
    Eli Lilly is giving a group of hospitals five days to comply with its new claims data policy or risk losing their 340B discounts. Some health centers aren’t cooperating with Lilly's recent push t…
    Endpoints · 1mo ago↗ source
  • FDA details flexibilities for new cell and gene therapies to leverage past data
    The FDA is further explaining to cell and gene therapy developers the types of prior knowledge companies can leverage for clinical, nonclinical and manufacturing-related work, according to new CBER…
    Endpoints · 1mo ago↗ source
  • Anti-aging biotech NewLimit raises $435M at $3B+ valuation
    The Bay Area startup NewLimit has closed one of biotech's largest private financings of 2026 and expects to start human testing next year for its first anti-aging drug candidate. NewLimit said…
← prev
page 16 of 32
next →
Hematology6
Pulmonology5
Infectious Disease4
Ophthalmology3
Dermatology2
Endpoints · 1mo ago
↗ source
  • What’s next for VEGF? #ASCO26 offered clues, but answers will have to wait
    CHICAGO — Not long ago, there were hopes that a new class of cancer drugs would repeat the success of Keytruda. Instead, it seems more likely they could end up making up for its weaknesses. Many ...
    Endpoints · 1mo ago↗ source
  • Male contraception startup closes $92.5M Series B; Novartis bets on actinium
    💸 Funding male contraception: Contraline closed a $92.5 million Series B financing to support a Phase 3 study of a male contraceptive dubbed NES/T. The daily treatment is a gel rubbed on the shoul…
    Endpoints · 1mo ago↗ source
  • Travere pays Everest $112M upfront to grow rare kidney disease pipeline
    Travere Therapeutics is enlisting the help of China-based Everest Medicines to bolster its rare kidney disease pipeline beyond its approved medicine Filspari. The San Diego biotech is doling out…
    Endpoints · 1mo ago↗ source
  • Legend Biotech shares first in vivo CAR-T data, its next act after Carvykti
    Legend Biotech’s long-awaited first showing of in vivo CAR-T data is here, fueling momentum in the growing field. Legend reported results Tuesday on 12 lymphoma patients from an investigator-init…
    Endpoints · 1mo ago↗ source
  • #ASCO26: Celcuity plans another FDA filing after positive breast cancer readout
    Celcuity said a combination regimen with its experimental drug gedatolisib doubled patients' likelihood of survival without disease progression or death in a late-stage breast cancer trial. Execu…
    Endpoints · 1mo ago↗ source
  • Citing 'dangerous deals,' lawmakers propose China restrictions
    A bipartisan group of Michigan lawmakers released a new bill that could greatly stifle the booming cross-border deals spree between Chinese and American biotechs. Rep. John Moolenaar (R-MI) and R…
    Endpoints · 1mo ago↗ source
  • #ASCO26: Roche details narrow failure of breast cancer pill trial
    Back in March, Roche revealed that the breast cancer pill on which it had pinned billion-dollar sales expectations had failed in a pivotal Phase 3 trial. Data presented Tuesday at ASCO reveal ...
    Endpoints · 1mo ago↗ source
  • Fulcrum ends sickle cell ambitions following regulatory feedback, will seek exit
    Fulcrum Therapeutics is scrapping its sole clinical-stage medicine after feedback from the FDA that referenced a recently pulled cancer drug from Ipsen. Fulcrum had planned to enter a registratio…
    Endpoints · 1mo ago↗ source
  • Cancer cases weigh down Abivax’s Phase 3 maintenance data in ulcerative colitis
    Abivax has proclaimed that its maintenance trial in ulcerative colitis delivered “landmark” results, and the drug's safety profile has previously been one of its main potential selling points. But…
    Endpoints · 1mo ago↗ source
  • Praxis sinks on late-stage study fail for seizure pill, halts second trial
    Praxis Precision Medicines has had a decent run over the past eight months or so, with two major clinical wins. But on Monday, the company disclosed a late-stage failure for its investigational s…
    Endpoints · 1mo ago↗ source
  • Obesity care startup Ilant Health raises $15M
    Ilant Health has raised $15 million in a Series A funding round to expand its personalized approach to treating obesity. Ilant is one of many virtual care companies competing to help employers an…
    Endpoints · 1mo ago↗ source
  • Updated: Allen Institute launches $400M effort to turn brain atlas lessons into medicines
    A Seattle-based nonprofit known for basic brain research is launching a $400 million initiative to translate its knowledge into drug development for neurodegenerative diseases, including Alzheimer'…
    Endpoints · 1mo ago↗ source
  • The cost of a PRV is twice as high as it was three years ago — and it’s likely to stay that way
    How much is a regulatory shortcut worth? The cost of a priority review voucher, which shortens the FDA’s standard review time by about four months, has roughly doubled in the last few years. The…
    Endpoints · 1mo ago↗ source
  • Epigenetic editing shows promise against chronic hep B infections
    A new method of CRISPR-based gene editing shows promise in curtailing chronic hepatitis B infections. Its twist is to silence disease-causing genes without altering the underlying DNA. Tune Thera…
    Endpoints · 1mo ago↗ source
  • Shionogi wins US approval for first pill to prevent Covid following exposure
    Japan's Shionogi on Monday said it won FDA approval for its oral antiviral to prevent Covid‑19 in adults and children older than 12 years who have been in contact with someone ...
    Endpoints · 1mo ago↗ source
  • #ASCO26: Lilly's plenaries; Incyte's frontline data in lymphoma
    Two plenaries related to Lilly: Researchers detailed findings from an investigator-sponsored trial using Lilly’s CDK4/6 inhibitor Verzenio in a rare cancer called dedifferentiated liposarcoma, show…
    Endpoints · 1mo ago↗ source
  • Agios licenses Oscotec drug; CEPI funds three potential Ebola vaccines
    🪪 Agios licenses Oscotec’s immune thrombocytopenia drug: Agios is paying $25 million upfront for exclusive global rights to Oscotec’s next-generation SYK inhibitor, called cevidoplenib. The South…
    Endpoints · 1mo ago↗ source
  • #ASCO26: Kelonia Therapeutics delivers an impressive in vivo CAR-T update
    CHICAGO — Eli Lilly in April signed an up to $7 billion deal to buy Kelonia Therapeutics, and now we know why. All 18 multiple myeloma patients who have received Kelonia’s in vivo CAR-T therapy ...
    Endpoints · 1mo ago↗ source
  • After being ditched by Candid, Rallybio finds Avenzo to take its Nasdaq listing
    Avenzo Therapeutics, one of the first biotechs to get major Western VC backing to in-license Chinese assets, will go public in a reverse merger with Rallybio. The Monday morning deal comes ...
    Endpoints · 1mo ago↗ source
  • Turn Therapeutics' eczema drug shows rapid response in mid-stage data
    California biotech Turn Therapeutics shared Phase 2 data for its topical atopic dermatitis treatment that show patients experienced symptom improvement faster than usual. In an interim analysis o…
    Endpoints · 1mo ago↗ source
  • Servier signs $1.55B upfront deal for Edgewise's muscular dystrophy assets
    Servier will pick up the muscular dystrophy business from Edgewise Therapeutics for $1.55 billion upfront, giving the French pharma company access to an experimental neuromuscular medicine that cou…
    Endpoints · 1mo ago↗ source
  • #ASCO26: AstraZeneca's triplet combo succeeds in liver cancer subgroup
    CHICAGO — AstraZeneca on Monday reported data from a new study showing the combination of a targeted treatment and two immunotherapies can benefit patients with certain kinds of liver cancer. Ind…
    Endpoints · 1mo ago↗ source